DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067)

Information source: Merck Sharp & Dohme Corp.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hepatitis C, Chronic

Intervention: Peginterferon alfa-2b (SCH 54031) (Biological); Ribavirin (SCH 18908) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Merck Sharp & Dohme Corp.

Official(s) and/or principal investigator(s):
Clinical Director, Study Director, Affiliation: Merck Sharp & Dohme Corp.

Summary

The current gold standard for treatment of chronic hepatitis C (CHC) patients is with pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness. This is the idea behind the development and usage of the PegPen. The goal of this study is to determine the satisfaction grade with this novel device.

Clinical Details

Official title: Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months

Detailed description: Enrollment of patients will occur in a sequential order of treatment initiation.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Adult patients with hepatitis C

Exclusion Criteria:

- According to the products' labeling.

Locations and Contacts

Additional Information

Starting date: October 2004
Last updated: April 7, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017